Director
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
Gaithersburg, MD, United States
Deidre Wilkins is a Director of Translational Scientific Management within AstraZeneca’s Vaccines & Immune Therapies unit. She received her undergraduate degree in Biochemistry from Pennsylvania State University and holds a Master’s Certificate in Healthcare Project Management from Villanova University. Deidre is also a certified Project Management Professional with over two decades of experience in drug discovery and development.
In her current role, Deidre provides scientific and technical leadership to support the development and validation of translational biomarkers across early- and late-stage clinical programs as well as the design and execution of viral surveillance studies. She has co-authored more than 25 scientific publications in support of AstraZeneca’s COVID-19 and RSV programs.
Her contributions to the nirsevimab clinical development program include managing two key viral surveillance studies: the Observational US Targeted Surveillance of Monoclonal Antibody Resistance Testing for RSV (OUTSMART RSV) and the International Network for Optimal Resistance Monitoring of RSV (INFORM RSV). Her recent work has explored the effects of nirsevimab administration on infants’ natural immune responses to RSV infection and the conservation of the nirsevimab epitope among circulating RSV strains.
Disclosure information not submitted.
Monday, October 20, 2025
2:45 PM - 2:57 PM US ET